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Introduction: Reliable animal models are required to evaluate novel treatments for
osteosarcoma. In this study, the aim was to implement advanced imaging techniques
in a murine model of orthotopic osteosarcoma to improve disease modeling and the
assessment of primary and metastatic disease.
Materials and methods: Intra-tibial injection of luciferase-tagged OPGR80 murine
osteosarcoma cells was performed in Balb/c nude mice. Treatment agent [pigment
epithelium-derived factor (PEDF)] was delivered to the peritoneal cavity. Primary tumors
and metastases were evaluated by in vivo bioluminescent assays, micro-computed
tomography, [18F]-Fluoride-PET and [18F]-FDG-PET.
Results: [18F]-Fluoride-PET was more sensitive than [18F]-FDG-PET for detecting early
disease. Both [18F]-Fluoride-PET and [18F]-FDG-PET showed progressive disease in the
model, with fourfold and twofold increases in standardized uptake value (p<0.05) by
the study endpoint, respectively. In vivo bioluminescent assay showed that systemically
delivered PEDF inhibited growth of primary osteosarcoma.
Discussion: Application of [18F]-Fluoride-PET and [18F]-FDG-PET to an established
murine model of orthotopic osteosarcoma has improved the assessment of disease. The
use of targeted imaging should prove beneficial for the evaluation of new approaches to
osteosarcoma therapy.
Keywords: osteosarcoma, luminescent measurements, x-ray microtomography, positron-emission tomography,
pigment epithelium-derived factor
Introduction
Osteosarcoma is the most common primary malignancy of bone and the second most common
cause of cancer-related death in the pediatric age group (1). Patients treated with surgical resection
and three-drug chemotherapy regimes have an overall 5-year survival rate of 70%. Patients who
do not respond to multi-agent chemotherapy have limited treatment options. Intensification of
treatment or substitution of chemotherapeutic agents has not proven to be of benefit to these
patients (2, 3).
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Osteosarcoma cells metastasize to the lungs and a number of
molecular pathways are being targeted in the development of
novel treatment agents. In order to evaluate these novel treatment
agents, it is critical that preclinical translational studies are per-
formed using reproducible animal models that closely simulate
human osteosarcoma.
Pigment epithelium-derived factor (PEDF) is a glycoprotein
that has shown promise in early laboratory studies as a targeted
anti-osteosarcoma agent. PEDF is an anti-angiogenic endogenous
glycoprotein that simultaneously targets osteosarcoma cells and
inhibits tumor vessel formation (4). In vivo studies evaluating
PEDF therapy havemade use of a clinically relevantmurinemodel
of orthotopic osteosarcoma. This model phenocopies the patho-
logical features and behaviors of human osteosarcoma (5). When
an intra-peritoneal micro-osmotic pump delivered PEDF system-
ically, the growth of well-established orthotopic osteosarcomawas
suppressed, and the burden of pulmonary metastatic disease was
reduced (6).
A key aim in this study was to improve the murine model
of orthotopic osteosarcoma by making use of advanced imaging
techniques; bioluminescence imaging, micro-computed tomogra-
phy, [18F]-Fluoride-PET and [18F]-FDG-PET. We sought to eval-
uate whether these imaging techniques could be used to provide
well-defined and reproducible endpoints for evaluating potential
therapies, such as PEDF, in the murine orthotopic model.
Materials and Methods
Osteosarcoma Cell Line
The luciferase-expressing OPGR80 cell line was derived from
a transgenic mouse model of conditional osteosarcoma. The
cell line was kindly donated by Dr. Carl Walkley (St. Vincent’s
Institute, Melbourne, VIC, Australia). In this model, osteoblast-
restricted deletion of p53 and pRb generate spontaneous multifo-
cal osteosarcoma (7). The luciferase-containing vector was kindly
provided by Dr. Andrew Kung (Dana-Farber Cancer Institute,
Boston, MA, USA). Luciferase and phosphotransferase sequences
were fused and introduced into a pMMP retrovirus to generate
pMMP-LucNeo. Cells were co-transfected with pMMP-LucNeo
and Eco Pac plasmid. Viral supernatants were then applied to
the OPGR80 cell line for 48 h. Luciferase-expressing cells were
selected with 1mg/mL neomycin (G418, Invitrogen, Carlsbad,
CA, USA).
OPGR80 cells were cultured under standard conditions of
37°C/5% CO2 in complete medium (CM), which consisted of
MEM-Alpha+GlutaMAX (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) and 1% antibiotic–antimycotic (Invitrogen, Carlsbad,
CA, USA).
MTS Proliferation Assay
OPGR80 cells were seeded in 96-well plates in CM, at a density
of 1 103 cells/well, 100μL/well. Cells were cultured under stan-
dard conditions for 24 h and then treated with PEDF at 0, 1.56,
3.125, 6.25, 12.5, 25, 50, and 100 nM concentrations in quadru-
plicate. After 48 h of exposure to the relevant treatment, 20μL of
CellTiter 96® AQueous One Solution Reagent (Promega, Madison,
WI, USA) was added to each well. This reagent contains the
tetrazolium compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) that
is bioreduced into a colored formazan. Cells were incubated with
the reagent for 3 h and absorbance was measured each hour at
490/655 nm using a Bio-Rad Model 680 micro-plate reader (Bio-
Rad, Philadelphia, PA, USA).
Animals and Ethics Approval
Animal Ethics Committees at St Vincent’s Hospital Melbourne
(033/10, 034/10) and Peter MacCallum Cancer Centre (E461)
approved all animal experimentations. Five-week-old Balb/c nude
mice were purchased from the Animal Resource Centre Australia.
Mice were kept in polycarbonate micro-isolator cages with
individual air supplies and temperature was maintained at 23°C,
with a 12-h light–dark cycle. Animals were handled at all times in
a laminar flow hood and were observed for behavioral changes,
such as abnormal grooming and foraging, inactivity, and lame-
ness. Mice were weighed using digital scales and were monitored
thrice weekly for tumor growth and signs of distress. Tumors
were measured in the anteroposterior (AP) and lateral (L) planes
using digital calipers. Leg volumewas calculated using the formula
4/3π[1/4(AP+ L))]2. The volume of the contralateral limb was
subtracted from that of the tumor-bearing limb to calculate tumor
volume, as previously described (6, 8).
Intra-Tibial Inoculation of OPGR80
Osteosarcoma Cells
Luciferase expression by OPGR80 cells was confirmed in vitro
prior to performing intra-tibial inoculations. OPGR80 cells
were seeded in duplicate in a 96-well opaque white Microtest™
plate (BD Biosciences, Franklin Lakes, NJ, USA) 100μL/well,
at concentrations of 2.5 105, 1.25 105, 6.25 104, and
3.125 104 cells/well. Cells were then incubated for 6 h under
standard conditions before the addition of 150μg/mL -luciferin
(Caliper LifeSciences, MA, USA). An in vitro bioluminescent
assay was then performed by centering the plate on the imaging
stage of the Xenogen IVIS® Spectrum imaging system. Total
flux for each well was measured using the auto-exposure and
auto-region of interest (ROI) functions of Living Image® software
(Caliper LifeSciences, MA, USA).
OPGR80 cell viability was confirmed by Trypan Blue exclu-
sion immediately prior to intra-tibial inoculation. Cells were
then mixed with 50% BD Matrigel™ Matrix (BD Biosciences,
Franklin Lakes, NJ, USA) to a concentration of 2 106 cells/mL.
BD Ultra-Fine Insulin Syringes (BD Biosciences, Franklin Lakes,
NJ, USA) were filled with 10μL of the OPGR80/Matrigel solu-
tion and kept on ice. Ten microliters of intra-tibial injections
were performed, as previously described by Dass et al. (5). Mice
were anesthetized with intra-peritoneal ketamine (100mg/kg)
and xylazine (10mg/mg). The left leg of each mouse was held
with the knee maximally flexed and the 29G needle tip was
placed at the tibial tuberosity. The needle was advanced using a
drilling motion to avoid fracture of the bone. The 10μL inocu-
lum was then injected and the needle retracted slowly to avoid
back-flow.
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Systemic Delivery of Treatment Agents
The day of orthotopic injection of osteosarcoma inoculum was
defined as day 0 of the study. Treatment was initiated at day 20 of
the study as per previous studies (6). The treatment groups were
as follows: (1) a control group of untreated tumor-bearing animals
(n= 6); (2) a group receiving sterile water as the vehicle by micro-
osmotic pump (n= 10); (3) a group receiving PEDF by micro-
osmotic pump (n= 10) at a continuous rate of 500μg/kg/day.
Water was used as the PEDFdiluent. Previous experiencewith this
method of PEDF delivery guided selection of the 500μg/kg/day
PEDF dose (6, 8).
Bioluminescent Assay In vivo
In vivo bioluminescent assays using the Xenogen IVIS were per-
formed at days 3, 6, 10, and 13 following intra-tibial injection of
the OPGR80 cell line. Tumor growth was determined by measur-
ing total flux of the primary tumors at each time point. Follow-
ing implantation of the micro-osmotic pump for PEDF delivery,
in vivo bioluminescent assays were performed at days 20, 24,
27, and 31.
Ten minutes prior to imaging, mice were given an intra-
peritoneal injection of -luciferin (150mg/kg, 15mg/mL, Caliper
LifeSciences, MA, USA). Mice were then anesthetized with isoflu-
rane/oxygen (5% induction, 2% maintenance) and were imaged
prone using the Xenogen IVIS® Spectrum imaging system. Expo-
sure times varied from 0.5 to 60 s.
Positron-Emission Tomography In vivo
Positron-emission tomography (PET) imaging was performed
in vivo utilizing [18F]-Fluoride and [18F]-fluorodeoxyglucose
(FDG) (Peter MacCallum Cancer Centre, East Melbourne, VIC,
Australia). Imaging with [18F]-Fluoride and [18F]-FDG were per-
formed on sequential days, 1 week after intra-tibial injection
(n= 6) and then at the study endpoint (n= 26).
For [18F]-FDG-PET imaging, mice fasted for at least 3 h were
anesthetized using 3% isoflurane in 50% oxygen in air and then
injected intravenously via the tail vein with 14.8MBq [18F]-FDG.
Anesthesia wasmaintained for a further 20min before the animals
were allowed to recover. At 90min after tracer injection, the
mice were anesthetized again before being placed on the bed of
a Philips Mosaic PET scanner and imaged over 10min. For [18F]-
Fluoride-PET imaging, unanesthetized animalswere injectedwith
14.8MBq [18F]-Fluoride and PET imaging performed 60min
later, as described above.
Positron-emission tomography scans were corrected for decay
and randomemissions before the imageswere reconstructed using
a 3D RAMLA algorithm. In-house analysis software (Marvn2.01)
was used for analysis and interpretation. A blinded single observer
defined the volume of interest at the site of the primary tumor and
calculated the maximum standardized uptake value (SUVmax),
target to background ratio (TBR), percentage of injected dose (%
ID), and metabolic tumor volume (MTV).
Experimental Endpoint and Tissue Processing
Whole body perfusion with 4% paraformaldehyde (PFA) was
performed at the humane endpoint of the study. Animals were
first anesthetized with isoflurane using a nose cone. Dissection
through the anterior abdominal and thoracic walls was performed
to reveal the heart. The infusion apparatus consisted of a Har-
vard Apparatus Syringe Pump S11 Plus (loaded with a 10mL
syringe containing 4%PFA), connected to a 26Gneedle by 0.4mm
polyethylene tubing. The needle was introduced into the left ven-
tricle of the heart and 2mL of 4% PFA was infused systemically,
at a rate of 9.49mL/h.
Micro-Computed Tomography Post-Mortem
Micro-computed tomography was performed post-mortem using
the SkyScan system (Bruker microCT, Belgium). Scans were per-
formed of the pelvis, femurs, and tibiae of non-dissected mice
using a 0.5mm aluminum filter, 50 kV voltage, and 98μA cur-
rent. 3D volumetric reconstruction was performed using the
SkyScan software NRecon (Caliper LifeSciences, MA, USA).
Reconstructed slices were viewed using SkyScan software CT-
Analyzer. Image segmentation was performed manually to define
the radio-dense tumor mass as the ROI. Adjacent cortical bone of
the tibia was excluded from the ROI. Tumor volume, radio-dense
tumor volume, and % radio-dense tumor were calculated, along
with tumor nodule number, separation, and thickness.
Tissue Histology
Tissues from six animals from each treatment group were pro-
cessed into paraffin blocks for histological examination. These six
animals had a primary tumor total flux (obtained at the study end-
point using the Xenogen IVIS® Spectrum imaging system) closest
to the median result for each treatment group. Orthotopic tumors
were dissected from the adjacent bone post-mortem and prepared
for histological examination thus avoiding need to decalcify tumor
tissues prior to cutting.
Four-micron-thick sections of primary tumor, lung, heart,
kidney, and liver were sectioned to achieve the greatest cross-
sectional area for examination. Three random sections, each sepa-
rated by 50μmdistance in the sample, weremounted on a slide for
evaluation. All tissues were stained with hematoxylin and eosin to
visualize tissue structure.
To detect tissue calcification, the primary tumor and lung
tissues were stainedwithAlizarin Red S, an anthraquinone deriva-
tive, to detect calcium-Alizarin Red S complexes, which are
birefringent under polarized light (9). Briefly, the sections were
immersed in Alizarin red S for 5min, excess stain blotted prior
to immersion into 100% acetone (20 dips), followed by 50% ace-
tone/xylene (20 dips) and 100% xylene solution (20 dips). The
sections were then cover-slipped in DPX and examined by light
and polarized microscopy.
Dewaxed primary tumor and lung tissues were stained with
indirect immunohistochemistry for CD31 and VEGF-A using
an autostainer (DAKO Autostainer, Botany, NSW, Australia).
Briefly, dewaxed sections were pre-treated with proteinase K for
8min (to detect CD31) or 0.1M citric acid buffer pH 6.0 (to detect
VEGF-A), followed by blocking of endogenous tissue peroxidase
by 3% hydrogen peroxide, three washes in tris-buffered saline
(TBS) pH 7.4 and 30min incubation in protein blocking solution
(DAKO, Carpinteria, CA, USA). The sections were then subjected
to 1-h incubation in purified rat anti-mouse anti-CD31 antibody
(BD Pharmingen, clone MEC 13.3, 1:100 dilution) or rabbit anti-
human polyclonal anti-VEGF (Abcam, Cambridge, UK, ab 46154,
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1:100 dilution). The unbound primary antibody was washed away
with TBS, followed by incubation in secondary polyclonal biotiny-
lated rabbit anti-rat IgG and swine anti-rabbit IgG conjugated to
HRP (both purchased from DAKO), to detect CD31 and VEGF-
A, respectively. To detect CD31 bound complex ABC Elite was
used (Vector laboratories, Burlingame, CA,USA), whereasVEGF-
A complex was detected by streptavidin-HRP (DAKO). Bound
complexes were visualized by diaminobenzidine (DAKO).
All stained sections were scanned and photographed using an
Olympus BX51 microscope, VS120 slide scanner, and Olympus
VS-ASWsoftware version 2.4. To examine if there was a difference
in the extent of tumor calcification between the experimental
groups, the Alizarin Red S staining was quantified from scanned
images using ImageJ software version 1.47a (National Institutes of
Health, USA) and expressed as percentage of total tumor tissue
examined.
Statistics
GraphPad Prism for Mac OS X (Version 5.0d) was used for all
statistics. Student’s t-test and ANOVA analysis with Bonferroni
multiple comparisons test were usedwhere appropriate. Data were
expressed as mean SEM, with p< 0.05 considered statistically
significant.
Results
PEDF Inhibits Proliferation of OPGR80 Cells
In vitro
MTS proliferation assay was performed to examine the effects
of PEDF on osteosarcoma cell proliferation in vitro. Prolif-
eration of OPGR80 cells was inhibited by PEDF treatment
in a concentration-dependent manner. Across the range of
tested concentrations (1.56, 3.125, 6.25, 12.5, 25, 50, 100 nM),
maximal inhibition was achieved by 100 nM PEDF treatment,
with a 28.7 3.56% reduction in absorption ratio demonstrated
(p< 0.01) (Figure 1).
FIGURE 1 |MTS proliferation assay. OPGR80 cell proliferation was
inhibited by treatment with PEDF in vitro.
Luciferase Expression by OPGR80
Osteosarcoma Cells
Prior to intra-tibial injection, the luciferase expression by the
OPGR80 cell line was determined. All seeded wells were seen
to contain luciferase-expressing cells on bioluminescent assay.
All concentrations of OPGR80 cells seeded were statistically dis-
tinguishable from the control wells and each other (p< 0.0001)
(Figure 2).
Primary Tumor Growth by Bioluminescent Assay
and Caliper Measurement
From day 3 after intra-tibial injection an exponential pattern of
growth of the primary tumorwas observed. At day 13, a significant
increase in primary tumor total flux was observed (p< 0.05).
Beyond day 13, a 7-day lapse between serial bioluminescent assays
was required to show significant tumor growth by primary tumor
total flux.
Treatment with PEDF was started at day 20. Average tumor
volume at day 20 was 7.50 1.48mm3. Treatment with PEDF
caused a significant reduction in tumor growth by day 31 of the
studywhen compared to the group receiving sterile water. Primary
tumor total flux was reduced by 51.21% (p< 0.001) at day 31
(Figure 3). Tumor volume, as calculated from anterioposterior
and lateral dimensions, fromday 20 to the study endpoint, showed
no significant difference between treatment groups (Table 1).
Primary Tumor Growth by PET Imaging
Imaging with [18F]-Fluoride and [18F]-FDG were performed on
sequential days, at days 8 and 9 of the study and at days 32 and
33. Maximum standardized uptake value (SUV), TBR, percentage
of injected dose (% ID), andMTV were calculated. [18F]-Fluoride
SUV was the most sensitive parameter for detecting early stage
disease in the OPGR80 orthotopic osteosarcoma model, with an
average [18F]-Fluoride SUV reading of 4.723, 1 week after intra-
tibial injection. Taking arbitrary cut-offs of 2.0 and 3.0 for SUV
and TBR, respectively, other readings obtained at week 1 were not
of sufficient magnitude to indicate malignancy (Figures 4A,B).
Between week 1 and the study endpoint, the sevenfold increase
in [18F]-Fluoride % ID was the greatest, making it the most
sensitive marker of disease progression. When results for [18F]-
Fluoride and [18F]-FDG are compared, the increases in SUV, TBR,
MTV, and % ID demonstrated for [18F]-Fluoride were of greater
magnitude than for [18F]-FDG (Figures 4A,B). Application of
PET imaging to examine the potential therapeutic effects of PEDF
showed that treatment with PEDF did not reduce primary tumor
progression.
Pulmonary Metastases by Bioluminescent Assay
and PET Imaging
In vivo bioluminescent assays were performed to monitor both
primary tumor and pulmonary metastases. Intrinsic dynamic
range limitations associated with the Xenogen IVIS and Living
Image software meant that imaging of primary tumor and pul-
monary metastases simultaneously was not possible. Shielding
was applied to the hind limbs ofmice before imaging of the thorax.
This allowed pulmonary metastatic disease to be identified, with-
out interference from the larger hind limb tumors. Isolated images
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FIGURE 2 | In vitro bioluminescent assay. Luciferase expression by the OPGR80 cell line was confirmed by in vitro bioluminescent assay prior to in vitro use.
FIGURE 3 | Primary tumor growth after treatment by in vivo bioluminescent assay. Total flux (p/s) for the primary tumor region of interest (ROI 1) was
determined at day 20, 24, 27, and 31. Primary tumor total flux is reduced by PEDF treatment at day 31 (*p<0.001). Photomicrographs taken at day 31 are shown.
of pulmonary metastases were collected at days 27 and 31 of the
study, although metastatic spread at an earlier time-point cannot
be ruled out.
At day 27 of the study, a total of 16 mice showed pulmonary
metastases on in vivo bioluminescent assay. By day 31, pulmonary
metastatic disease could be identified in a further seven mice. At
day 31 of the study, six mice receiving water as control showed
evidence of pulmonary metastatic disease compared to two mice
receiving PEDF. For those animals that did possess metastases at
day 27 and 31, the mean total flux for pulmonary metastases was
determined. Treatment with PEDF did not affect themean burden
of pulmonary metastases in these animals (Figure 5).
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TABLE 1 | Tumor volumes (PEDF 500μg/kg/day versus water).
Day Water
(mm3)
PEDF
500μg/
kg/day
(mm3)
Difference
(mm3)
95% CI
of diff. (mm3)
t p Value
20 8.555 4.943  3.611  20.42 to 13.20 0.6587 p>0.05
24 22.32 20.22  2.094  16.62 to 12.43 0.4421 p>0.05
27 21.92 17.15  4.772  19.30 to 9.752 1.007 p>0.05
31 24.22 24.35 0.1317  14.39 to 14.66 0.02780 p>0.05
In vivo bioluminescent assays for the identification of pul-
monary metastases were performed for all animals on the day
prior to PET imaging. The [18F]-Fluoride and [18F]-FDG-PET
scans obtained for animals with known pulmonary metastases
were examined. The resolution of the PET images obtained would
not allow for reliable identification of pulmonary lesions in any
animal.
Post-Mortem Assessment of Tumor by
Micro-Computed Tomography
Heterogeneous radio-density of the OPGR80 orthotopic osteosar-
coma allowed demarcation and segmentation of the tumor as a
ROI (Figure 6A). Animals treated with PEDF exhibited tumors
that were less radio-dense when compared to the control group.
PEDF treated animals possessed tumors that were 24.90 2.77%
mineralized compared to 35.27 1.99% for the control group
(p< 0.05). The PEDF treated group possessed tumors with
reduced tumor nodule thickness. Mean tumor nodule thickness
was reduced by 27% for PEDF treated animals (p< 0.01). There
was no significant difference between treatment groups for tumor
volume, mineralized tumor volume, tumor nodule number, and
tumor nodule separation (Figure 6B).
Histological Assessment
Primary Tumors
Hematoxylin and eosin stained sections demonstrated tumor tis-
sue consisting of pleomorphic spindle-shaped cells producing
an eosinophilic matrix. Variable degrees of tumor differentiation
were seen both within individual samples and across treatment
groups. Some tumors consisted solely of pleomorphic spindle
cells, while others showed a peripheral zone of invadingmalignant
cells surrounding a central zone of increased matrix produc-
tion. All sections showed cells at the margin of the tumors were
observed infiltrating between striated skeletal muscles. Cells were
also observed invading neurovascular structures (Figure 7A).
No distinct tumor morphological patterns have been observed
between the treatment groups.
The potential anti-angiogenic effect of PEDF on tumor vas-
cularization was examined by identifying CD31-positive vessels
and regions of VEGF-A production in the stained tissue. Periph-
eral regions consisting primarily of invading malignant spindle-
shaped cells possessed a fine network ofCD31-positive vessels that
were closely associated with VEGF-A-producing stromal cells.
Although individual CD31-positive inflammatory cells were evi-
dent in the surroundings of the central calcified zone, the CD31-
positive vessels, and VEGF-A positive cells were largely absent
from the central calcified zone of the tumors (Figures 7B,C).
Alizarin Red S staining of tumor tissue showed the cen-
tral eosinophilic regions of tumor to be birefringent under
polarized light indicating that the region was largely calcified
(Figures 7D–F). Quantification of Alizarin Red S-calcium com-
plex showed that tumors obtained from control animals contained
36.68 6.273% calcified material, whereas tumors treated with
500μg/kg/day PEDF contained 36.94 2.099% of calcified mate-
rial. No statistically significant difference in the degree of tumor
calcification was observed between treatment groups.
Pulmonary Metastases
Pulmonary metastases were observed as clusters of tumor cells
within the native alveolar architecture of the lung (Figure 7G).
As was observed for orthotopic primary tumors, variable degrees
of matrix production and calcification were demonstrated. At
one end of the spectrum, metastatic lesions consisted primarily
of tumor cells with minimal matrix production, while at the
other end of the spectrum, metastases consisted of a highly
cellular peripheral zone surrounding a region of matrix pro-
duction and calcification. Positive staining with Alizarin Red
S that was birefringent under polarized light confirmed this
(Figures 7H–I).
Quantification of lung metastases in a maximal en face cross-
sectional area showed no statistical difference between treat-
ment groups based on either number of metastatic lesions
per section or the cross-sectional area of these lesions. For ani-
mals treated with PEDF (500μg/kg/day), 2.833 1.138 metas-
tases were counted per lung section compared to 2.167 1.108
metastases for the control group. The mean cross-sectional area
of micrometastatic lesions was 1.856 106 4.405 105 μm2 for
control animals, while animals treated with PEDF possessed pul-
monarymicrometastasesmeasuring 2.08 106 1.08 106 μm2.
Quantification of Alizarin Red S–calcium containing tumor
tissue in pulmonary metastases showed that control animals
lesions contained 14.9 4.9% calcified tissue compared to
14.09 3.018% for animals treated with PEDF (500μg/kg/day).
This difference was not statistically significant.
Pulmonary micrometastases are vascularized by an irregular
and delicate network of CD31-positive vessels. Similarly to pri-
mary orthotopic tumors, the vascularization occurred primarily
in the highly cellular peripheral zones of the tumor mass. VEGF-
A producing cells, that on histological examination appear to be
inflammatory cells, were confined to periphery of the calcified
region. Significant inflammatory cell population was observed
surrounding the lung metastases, whereas in primary orthotopic
tumors, the inflammatory cells were scattered throughout the
tumor tissue andwere particularly prominent at the invading front
of the tumor tissue.
Discussion
In this study, we report a preclinical murine model of orthotopic
osteosarcoma employing the transgenic OPGR80 osteosarcoma
cell line. The model is characterized by the deposition of cal-
cified material within the orthotopic tumor tissue as well as in
pulmonarymetastases. These featuresmake it distinct from previ-
ously used models. Earlier in vivo studies used the SaOS-2 human
osteosarcoma cell line, which gave rise to undifferentiated tumors
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FIGURE 4 | (A) Positron-emission tomography parameters obtained 1week
following intra-tibial injection and at the study endpoint (SUV, standardized
uptake value; TBR, tumor to background ratio; MTV, metabolic tumor volume;
*p<0.05). [18F]-Fluoride SUV was the most sensitive parameter for detecting
early stage disease. Between week 1 and the study endpoint, the sevenfold
increase in [18F]-Fluoride % ID was the greatest, making it the most sensitive
marker of disease progression. (B) [18F]-Fluoride and [18F]-FDG-PET imaging
were performed at the end of week 1 and the study endpoint. Images show
increased uptake of the PET tracer in the left hind limb of the mouse. Pulmonary
metastatic disease was not detectable on PET imaging.
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FIGURE 5 | Detection of pulmonary metastases by in vivo
bioluminescent assay. Shielding was applied to the hind limbs of mice before
imaging of the thorax. This allowed pulmonary metastatic disease to be
identified. Total flux (p/s) for the region of interest (ROI) was determined at day
27 and 31. Photomicrographs taken at day 31 are shown. Treatment with PEDF
did not affect the mean burden of pulmonary metastases in these animals.
consisting of pleomorphic spindle cells with little extracellular
matrix (6, 8, 10, 11). In this study, we sought to improve the
replication of the human condition by themodel, and to assess pri-
mary andmetastatic osteosarcoma through the implementation of
advanced imaging techniques.
Pigment epithelium-derived factor inhibited proliferation of
OPGR80 osteosarcoma cells in vitro. The viability of OPGR80
cells treated 100 nM PEDF was reduced by 28.7 3.56%. When
SaOS-2 and SJSA-1 human osteosarcoma cell lines were treated
with 100 nM PEDF, the viability of these cells lines was reduced
by 13.8 and 36.4%, respectively (6). Reduced osteosarcoma cell
proliferation with PEDF treatment has previously been attributed
to the induction of osteosarcoma cell apoptosis and the inhibition
of cell cycle progression (12).
No previous studies have allowed comparison of biolumines-
cent imaging and PET imaging in a murine model of orthotopic
osteosarcoma. Studies using the SaOS-2 human osteosarcoma
cell line, without a luciferase reporter gene, were unable to
confirm tumor establishment in the tibia until day 20 after
intra-tibial inoculation (6, 8). In the current study, in vivo
bioluminescent assays performed at day 3 after intra-tibial
inoculation of the OPGR80 osteosarcoma cell line confirmed
that all mice possessed biologically active tumor cells in the
left hindlimb. PET imaging at day 9, using the [18F]-FDG
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FIGURE 6 | (A) Rendered 3D reconstruction obtained by micro-computed
tomography. The tumor attached to the proximal tibia is a
heterogeneously mineralized mass. (B) Primary tumor characteristics by
micro-computed tomography. Heterogeneous radio-density of the
OPGR80 orthotopic tumor allowed demarcation and segmentation of the
tumor as a region of interest (ROI). Tumor volume, radio-dense tumor
volume, percentage radio-dense tumor volume, tumor nodule number,
thickness, and separation were determined. Animals treated with PEDF
(500μg/kg/day) exhibited tumors that were less radio-dense when
compared to the control group.
radioactive tracer, did not allow early identification of disease.
[18F]-Fluoride SUV was the only PET parameter that indicated
early disease, with an average [18F]-Fluoride SUV reading of
4.723 at day 8. Taking arbitrary cut-offs of 2.0 and 3.0 for
SUV and TBR, respectively, other parameters at days 8 and 9
were not of sufficient magnitude to indicate malignancy. The
early identification of biologically active tumor cells by in vivo
bioluminescent imaging or [18F]-Fluoride SUV is beneficial when
closely monitoring disease progression in an animal model such
as this.
Treatment with PEDF caused a significant reduction in tumor
growth by day 31 of the study by in vivo bioluminescent assay.
Primary tumor total flux was reduced by 51.21% (p< 0.001) at
day 31. Reduced tumor growth by in vivo bioluminescent assay
and absence of a therapeutic effect demonstrated on digital caliper
measurement, in addition to the much earlier confirmation of
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FIGURE 7 | Histological assessment. (A) Hematoxylin and eosin
(H&E) stained section of undifferentiated primary tumor (t). Tumor cells
(arrows) are observed infiltrating the adjacent skeletal muscle (m);
(B) Immunohistochemistry for CD31 showing positively stained endothelium
(arrows), within both muscle and tumor; (C) Immunohistochemistry for
VEGF-1 showing positively stained cells within the peripheral region of the
tumor (arrows); (D) H&E stained section of tumor and adjacent skeletal
muscle (m). The tumor consists of a highly cellular peripheral zone (p) and a
matrix-producing central zone (c); (E) Alizarin Red S stained tumor
identifying the presence of deposited calcium as dark red precipitate (arrow)
within the central zone; (F) Alizarin Red S stained tumor under polarized
light confirms the presence of calcium within tissue evident here as bright
red precipitate; (G) H&E stained lung tissue (l) with metastatic lesion
(contained within solid line). The metastasis possesses a matrix-producing
central zone (c); (H) Alizarin Red S stained section showing the presence of
calcium as dark red precipitate in the central zone (arrow); (I) Alizarin Red S
stained lung tissue under polarized light. Calcified regions are evident as
bright red precipitate.
tumor establishment in bone, suggests that the use of serial
bioluminescent assays is a sensitive method for detecting and
monitoring osteosarcoma progression in the OPGR80 model.
The murine model of orthotopic osteosarcoma reported here
is the first model to utilize PET imaging, with [18F]-Fluoride
and [18F]-FDG radioactive tracers, to evaluate PEDF therapy.
While treatment with PEDF did not reduce primary tumor pro-
gression, a number of findings warrant discussion as the model
is likely to be used further for the assessment of other novel
anti-osteosarcoma agents. [18F]-Fluoride-PET was more sensitive
than [18F]-FDG-PET for detecting early disease in the OPGR80
model. Furthermore, while both [18F]-Fluoride-PET and [18F]-
FDG-PET showed statistically significant increases in PETparam-
eters between week 1 and the study endpoint, the sevenfold
increase in [18F]-Fluoride % ID was the greatest, making it the
most sensitive marker of disease progression. Osteosarcoma is a
tumor characterized by the production of osteoid, which becomes
mineralized in better-differentiated tumors. TheOPGR80 cell line
used in the study gave rise to a model that is heavily charac-
terized by calcification of both primary and metastatic lesions.
The increased sensitivity of [18F]-Fluoride-PET is in line with this
characteristic.
Post-mortem micro-computed tomography showed that
tumors treated with PEDF were less radio-dense than those
of control animals, an attribute that may be accounted for
by reduced tumor nodule thickness. However, post-mortem
histological assessment of tumor calcification by Alizarin Red S
staining did not show a statistical difference between treatment
groups. A more comprehensive study utilizing stereo-logical
3D volumetric counting may be of benefit. It is important to
note here that the analysis of radio-density on micro-computed
tomography was performed by segmentation of 3D volumetric
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reconstructions, while percent Alizarin Red S staining was
obtained from representative tissue sections.
The strength of the current study lies in its use of multiple
modalities for the assessment of primary and metastatic osteosar-
coma progression. Indeed, a similar approach is used in the
human condition for evaluation of primary tumors and staging.
Radiographs, CT, MRI, bone scan, and PET are all used clini-
cally to characterize both primary and metastatic disease. PET
in particular plays a role in staging, prognostication, and may
guide surgical treatment. For FDG-avid sarcomas, PET may be
used to guide biopsy of regions with the most intense uptake,
which are likely to represent the highest grade of disease (13, 14).
PET is also useful for the diagnosis of sarcomatous chance in
the setting of neurofibromatosis and chondromatosis.When FDG
avidity is present at the time of diagnosis, a baseline is obtained
for assessing the response to adjuvant therapy, an indicator of
prognosis (15). Additionally, when a poor response to adjuvant
therapy is seen, wider surgical margins may be considered. In
the current study, serial PET evaluation demonstrated disease
progression in the orthotopic murine model and was unable to
identify metastatic lesions. While the purpose of this study was
not to clarify the role of PET in staging and treating osteosarcoma,
the results here provide proof of principle that [18F]-FDG- or
[18F]-Fluoride-PET may be useful for evaluating novel treatment
agents using the orthotopic murinemodel of osteosarcoma. In the
future, advanced imaging and targeted probes for osteosarcoma
may assist with staging and treating human disease.
Limitations of the study include the use of a transgenic murine
osteosarcoma cell line rather than a human cell line, and the
inability to compare systemic PEDF treatment to a mainstay
chemotherapeutic. While a therapeutic response to PEDF was
demonstrated on in vivo bioluminescent imaging the significance
of this finding cannot be concluded without reference to an agent
with an established therapeutic effect.
Conclusion
This study demonstrates the value of advanced imaging tech-
niques in the study of tumor growth, invasion, and metastasis.
In vivo bioluminescent imaging and [18F]-Fluoride-PET allow
early identification of disease in the OPGR80 murine model
of orthotopic osteosarcoma. Both [18F]-Fluoride-PET and [18F]-
FDG-PET have demonstrated disease progression. High uptake of
[18F]-Fluoride in tumor provides a greater potential for detection
of signal modulation by therapeutic intervention.
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